Journal
CANCERS
Volume 12, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/cancers12071889
Keywords
adeno-associated virus (AAV) vectors; transductional targeting; transcriptional targeting; hallmarks of cancer; apoptosis; tumor angiogenesis; immunotherapy; vaccine; CAR-T cells
Categories
Funding
- BMBF
- MWK Lower Saxony-funded Professorinnenprogramm Niedersachsen
- DFG-funded cluster of excellence REBIRTH
- Wilhelm-Sander Foundation
Ask authors/readers for more resources
Adeno-associated virus (AAV) vectors have gained tremendous attention as in vivo delivery systems in gene therapy for inherited monogenetic diseases. First market approvals, excellent safety data, availability of large-scale production protocols, and the possibility to tailor the vector towards optimized and cell-type specific gene transfer offers to move from (ultra) rare to common diseases. Cancer, a major health burden for which novel therapeutic options are urgently needed, represents such a target. We here provide an up-to-date overview of the strategies which are currently developed for the use of AAV vectors in cancer gene therapy and discuss the perspectives for the future translation of these pre-clinical approaches into the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available